http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021094308-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3cd4efdf582a23a35a134a1de9b3e4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9d4ccd9f689870178f224af28fb23b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-45 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56905 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-45 |
| filingDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98f19ebaaf081214388a0299979981ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eacdcf436b833afabcbd4275bbab0f5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdccec9d781a9cdd14025dfca55e492a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4167df1999dd3884b84121898bff29f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36f9b1f1181f16cf148e1429473bd332 |
| publicationDate | 2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021094308-A1 |
| titleOfInvention | New serological marker for the latent form of toxoplasmosis |
| abstract | In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice. Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst. Furthermore, newborn infants with a confirmed congenital toxoplasmosis display significantly higher anti-BCLA IgGs at birth when compared to their mother, suggesting a specific in-utero neosynthesis of such IgGs. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023280807-A1 |
| priorityDate | 2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.